Logo
Contact Us
Clinicogenomics

Guide Early Discovery for Clinical Development

Enrich real-world oncology patient data with comprehensive genomic profiling information to discover hidden patterns and inform early-stage drug discovery research.

Contact Us
Group 48
Use Cases

Future-Plan for Clinical Research and Development

Clinicogenomics is an optional add-on designed to enrich our robust oncology patient data with genomic markers to help generate insights about new research and development opportunities.

Genomic Data Includes:

  • Genomic data from multiple vendors including both large panel and whole exome/whole transcriptome sequencing
  • SNVs, indels, copy number alterations, fusions, rearrangements, and gene expression levels
  • Reported sequencing results summary
  • Raw data outputse VCF, BAM files
  • Genomic signatures:
  • 1. Homologous recombination repair (HRR)
  • 2. Homologous recombination deficiency (HRD)
  • 3. Micro satellite Instability (MSI)
  • 4. Tumor Mutational Burden (TMB)
  • Other:
  • 1. HLA class 1 genotyping
  • 2. HLA class 1 and 2 levels of expression
  • 3. Cell clonality

    4. Viral infections (EBV, HPV, TTV)
Group 213

COTA by the Numbers

2.1M+ Cancer Patient Lives

50/50 Academic vs. Community Treatment Setting

3 Approvals Supported

9 Hematology and Solid Tumor Diagnoses

5-Year Average Follow-up

2X Higher Inclusion Percentage in ECA vs. Competitor

Group 203
Additional Support

Get the Most of Your Clinicogenomics Data with Real-World Insights and Support

Real-World Support gives you access to industry veterans who can help you structure study designs, provide guidance on protocol and analysis,
make recommendations for regulatory submission packets, review research and manuscripts, and more to ensure your research achieves the highest quality standards.

Learn More
Resources

Fueling the Future of Cancer Research

Explore our collection of clinical research, recent press, podcasts, and more.

News
3 min read

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

NEW YORK–(BUSINESS WIRE)–COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading...

Read More
News
3 min read

Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence

Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc.,...

Read More
News
3 min read

COTA and PHI, a subsidiary of Texas Oncology, partner to deliver precision medicine for cancer patients

For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power...

Read More
View All Resources

Find Your Next Breakthrough

Discover the power of real world cancer data to help you understand patient journeys across the oncology spectrum and inform research directions.
Contact Us
Group 11
Logo
footer-background
Solutions
Products & Services
About Us
Follow Us
© 2025 COTA. All rights reserved.